Zirconium-89 radio-nanochemistry and its applications towards the bioimaging of prostate cancer

Publication date: Available online 1 August 2019Source: Inorganica Chimica ActaAuthor(s): F. Cortezon-Tamarit, A. Baryzewska, M. Lledos, S.I. PascuAbstractIn recent years, the use of metallic isotopes for nuclear imaging techniques such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) has become an area of much interest. In particular, PET is a molecular imaging modality that relies on the detection of two antiparallel, co-linear gamma rays (511 keV) emitted when a positron undergoes annihilation with an electron. PET isotopes of interest in medical practice are numerous and their use depends on their half-lives and introduction in the compounds of interest. These include: nitrogen-13 (t1/2 = 10 min), carbon-11 (t1/2 = 20 min), fluorine-18 (t1/2 = 110 min) and metallic isotopes such as gallium-68 (t1/2 = 68 min), titanium-45 (t1/2 = 3.08 h), copper-64 (t1/2 = 12.7 h), manganese-52 (t1/2 = 5.59 d) or zirconium-89 (t1/2 = 3.3 d). 89Zr has emerged as a promising isotope for radiotracer design and in vivo delivery, on basis of its ideal half-life matching the biological half-life of antibodies, antibody fragments and nanomedicines leading to high-resolution PET images for the pre-clinical and clinical investigations of a number of conditions including the prospective use in prostate cancers in the search of new diagnostic biomarkers. The availability of a plethora of chelators satisfying the coordination number of 8 such as siderop...
Source: Inorganica Chimica Acta - Category: Chemistry Source Type: research